BOSTON (Dec. 7, 2020, 9:00 a.m. EST)-The omega-3 fatty acids EPA and DHA work differently against chronic inflammation, according to the results of a small randomized study, suggesting each has its own important role to play in regulating the immune system.
The 34-week trial, led by researchers at the (HNRCA), compared the effects of the two omega-3s in a small group of older adults with obesity and chronic low-grade inflammation. The participants were randomly assigned to receive either EPA or DHA supplements twice a day. The results are published today in Atherosclerosis.
EPA and DHA, plentiful in fish and shellfish, have, in some studies, been linked to lower risk of heart disease and are believed to work by reducing inflammation. The results showed that DHA had a stronger anti-inflammatory effect than EPA:
- DHA lowered the genetic expression of four types of pro-inflammatory proteins, whereas EPA lowered only one type.
- DHA lowered white blood cell secretion of three types of pro-inflammatory proteins, whereas EPA lowered only one type.
- DHA also reduced levels of an anti-inflammatory protein, whereas EPA did not.
However, EPA improved the balance between pro- and anti-inflammatory proteins:
- After being metabolized, EPA produced by-products that were associated with immune function regulation and worked differently from those derived from DHA.
“The jury has been out, so to speak, on how the two major components of fish oil work – and whether one might be better than the other. These results suggest that DHA is the more powerful of the two on markers of inflammation in the body, but that’s not the end of the story,” said , a scientist on the Cardiovascular Nutrition Team at the HNRCA.
Lamon-Fava is also chair of the Division of Biochemical & Molecular Nutrition and an associate professor at the Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts.
“In our bodies, there is always this balance between pro-inflammatory and anti-inflammatory proteins, and we found EPA was better than DHA at enhancing that balance. For the prevention of cardiovascular disease, previous research tells us that balance is very important,” explained first author Jisun So, who did this work as part of her dissertation at the Friedman School, working on the Cardiovascular Nutrition Team at the HNRCA.
According to the , adults should consume at least two servings of seafood (4 ounces per serving) weekly. Salmon, cod, sardines, trout and light, canned tuna are good sources of EPA and DHA.
“Our study gives us a snapshot of how EPA and DHA may work to reduce chronic inflammation, and how each has distinct effects. Our results provide insight for future research to explore why that is the case and who would benefit from one or both of these healthy fats,” Lamon-Fava said.
Methodology
The study was a double-blind trial, meaning neither the participants nor the laboratory workers or scientists knew which supplement each individual received. The 21 participants received EPA or DHA supplements in a sequence that included supplement-free periods to create a blank slate from which to measure the impact of each supplement. During a lead-in phase, participants took supplements containing only high-oleic sunflower oil (similar to olive oil and not containing omega-3 fatty acids), to create a basis for comparison.
Authors and funding
Additional authors on the study are Dayong Wu, Alice H. Lichtenstein, and Nirupa R. Matthan at the HNRCA; Albert K. Tai at Tufts University School of Medicine; and Krishna Rao Maddipati at Wayne State University.
This work was supported by the U.S. Department of Agriculture’s ³Ô¹ÏÍøÕ¾ Institute of Food and Agriculture through an Agriculture and Food Research Initiative grant and by The Drs. Joan and Peter Cohn Research Fund. Any opinions expressed in this paper are those of the authors and not the funders. None of the authors disclosed conflicts of interest.
Citation
So, J., Wu, D., Lichtenstein, A.H., Tai, A.K., Matthan, N.R., Maddipati, K.R., and Lamon-Fava, S. (2020). EPA and DHA differentially modulate monocyte inflammatory response in
subjects with chronic inflammation in part via plasma specialized
pro-resolving lipid mediators: A randomized, double-blind, crossover study. Atherosclerosis. .
